SCHEMBL23833207

SCHEMBL23833207

COC(=O)CCCC#Cc1cccc(OCC(CCC(N)=O)NC(=O)OC(C)(C)C)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 7/20 0.38
▸ REN P00797 2/20 0.35
▸ PPARG P37231 2/20 0.34
▸ PPARA Q07869 2/20 0.34
▸ SCN9A Q15858 3/20 0.33
▸ HDAC3 O15379 2/20 0.32
▸ HDAC4 P56524 2/20 0.32
▸ HDAC1 Q13547 2/20 0.32
▸ HDAC7 Q8WUI4 2/20 0.32
▸ HDAC2 Q92769 2/20 0.32
▸ HDAC10 Q969S8 2/20 0.32
▸ HDAC11 Q96DB2 2/20 0.32
▸ HDAC8 Q9BY41 2/20 0.32
▸ HDAC6 Q9UBN7 2/20 0.32
▸ HDAC9 Q9UKV0 2/20 0.32
▸ HDAC5 Q9UQL6 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23833204 1.00 AAK1 (0.38) AAK1RENPPARGPPARASCN9A
SCHEMBL30193131 0.95 AAK1 (0.39) AAK1RENSCN9AHDAC3HDAC4
SCHEMBL22526117 0.95 AAK1 (0.39) AAK1RENSCN9AHDAC3HDAC4
SCHEMBL23832968 0.95 AAK1 (0.39) AAK1RENSCN9AHDAC3HDAC4
SCHEMBL26238218 0.93 AAK1 (0.38) AAK1RENSCN9AHDAC3HDAC4
SCHEMBL23845226 0.91 AAK1 (0.37) AAK1RENPPARGPPARAHDAC3
SCHEMBL22526123 0.90 AAK1 (0.40) AAK1SCN9AHDAC3HDAC4HDAC1
SCHEMBL30169109 0.90 AAK1 (0.40) AAK1SCN9AHDAC3HDAC4HDAC1
SCHEMBL22526644 0.89 AAK1 (0.38) AAK1RENHDAC3HDAC4HDAC1
SCHEMBL26238469 0.88 AAK1 (0.37) AAK1RENALDH1A1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
CN-115776891-A STAT degradants and uses thereof 凯麦拉医疗公司 2023-03-10 — — CN disclosed
EP-4121055-A1 STAT DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-01-25 — — EP disclosed
WO-2021188696-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 AAK1 2860/4885REN 2661/4885PPARG 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback